Company adds established oncology expert to leadership team
CULVER CITY, Calif.--(BUSINESS WIRE)--
NantHealth,
Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized
healthcare company, announced today the appointment of Sandeep
(Bobby) Reddy, MD, as Chief Medical Officer. In his new position,
Dr. Reddy will be responsible for overseeing education, outreach,
clinical development programs, and clinical trials for GPS
Cancer™, a comprehensive, molecular profile and NantHealth's
proprietary revolutionary pan-omic cancer analytic platform.
“Appointing Dr. Reddy and his experience to our leadership team will be
highly valuable to the evolution of the GPS Cancer initiative,” said Dr.
Patrick Soon-Shiong, founder and CEO of NantHealth. “With extensive
background in hematology, medical oncology and therapeutics research,
Dr. Reddy will play a key role in helping NantHealth achieve victory in
the war against cancer.”
Dr. Reddy joined NantHealth in December of 2016 as Senior Executive
Director of Medical Affairs and prior to that position, he served as
Chief Medical Officer at Caris Life Sciences. Over the course of his
career, Dr. Reddy has produced over 100 abstracts at major medical
conferences and over 30 peer-reviewed publications since 2014.
“The milestones that NantHealth has achieved in just over a year have
established the company as a proven disrupter – national and
international insurance coverage of the GPS Cancer profile, multiple
partnerships with leading medical institutions and joining experts in
the cancer community are immense efforts to take on and in such a
condensed timeframe,” said Dr. Reddy. “I’m thrilled to be a part of an
initiative that has potential to change the way we approach and treat
cancer. Dr. Soon-Shiong is a true visionary and I’m looking forward to
working with such an inspirational group of leaders to build further
awareness of the benefits that GPS Cancer has to offer the oncology
market.”
Dr. Reddy’s additional experience includes servicing as Chief of Staff
at Los Alamitos Medical Center and actively practicing clinical
hematology and oncology. Simultaneously, he held an adjunct faculty
position at the Geffen/UCLA School of Medicine as a clinical instructor
at Harbor-UCLA Medical Center, where he was awarded the distinguished
teaching award for clinical faculty in 2006. He is a member of the Los
Angeles Biomedical Institute, American Society of Clinical Oncology
(ASCO), International Association for the Study of Lung Cancer (IASLC)
and current SWOG investigator. His medical training includes fellowship
training in hematology and medical oncology and therapeutics research at
the City of Hope in Duarte, CA and Internal Medicine residency at
Harbor-UCLA Medical Center. Dr. Reddy received his MD from the
Geffen/UCLA School of Medicine after receiving his BS in biomedical
sciences at the University of California, Riverside.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the capabilities and
anticipated utility of our GPS Cancer, including predicting patient
response and resistance to therapeutics, enabling diagnoses by
physicians and accelerating efforts to bring novel combinations of
therapeutic agents to cancer patients. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results. Factors
that may cause future results to differ materially from management’s
current expectations include, among other things, that GPS Cancer may
not perform as anticipated, that sufficient physicians may not adopt GPS
Cancer to assist their diagnoses or that healthcare payers may not
provide reimbursement for GPS Cancer as expected. Our business is
subject to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our ability
to successfully launch new products and applications; competition; our
sales, marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; unanticipated
increases in costs or expenses; and risks associated with international
operations. Information on these and additional risks, uncertainties,
and other information affecting our business and operating results can
be found in our existing and future filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of
the date hereof. We disclaim any obligation to update these
forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissues and integrates
this molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system, which includes its unique
software, middleware and hardware systems infrastructure that collects,
indexes, analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and traditional
sources, continuously improves decision-making and further optimizes our
clinical pathways and decision algorithms over time. For more
information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through NantHealth.
GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome
(RNA) sequencing, and quantitative proteomics through mass spectrometry,
providing oncologists with a comprehensive molecular profile of a
patient's cancer and an assessment of protein pathway function to inform
personalized treatment strategies. GPS Cancer scanning is conducted in
CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer
Breakthroughs 2020, the world's most comprehensive cancer
collaborative initiative seeking to accelerate the potential of
combination immunotherapy as the next generation standard of care in
cancer patients. For more information, visit www.gpscancer.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170510005535/en/
NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com
Source: NantHealth, Inc.